GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Purchase Of Property, Plant, Equipment

EVAX (Evaxion Biotech AS) Purchase Of Property, Plant, Equipment : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Purchase Of Property, Plant, Equipment?

Evaxion Biotech AS's purchase of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means Evaxion Biotech AS spent $0.00 Mil on purchasing property, plant, equipment. Evaxion Biotech AS's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00Mil.

Compared with last quarter ($0.00 Mil in Jun. 2024 ), Evaxion Biotech AS spent the same money on purchasing property, plant, equipment in Sep. 2024 ($0.00 Mil).

Evaxion Biotech AS Purchase Of Property, Plant, Equipment Historical Data

The historical data trend for Evaxion Biotech AS's Purchase Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Purchase Of Property, Plant, Equipment Chart

Evaxion Biotech AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Property, Plant, Equipment
Get a 7-Day Free Trial -0.07 -0.36 -1.30 -0.29 -0.09

Evaxion Biotech AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Purchase Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Evaxion Biotech AS Purchase Of Property, Plant, Equipment Calculation

The amount used to purchase PPE.

Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evaxion Biotech AS Purchase Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Purchase Of Property, Plant, Equipment
Comparable Companies
NLTX NXTC INAB LVTX LUMO ELDN PMN PTN MAIA LTRN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970
Website
https://www.evaxion-biotech.com
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.